STOCK TITAN

Aquestive Therapeutics (AQST) CLO receives restricted stock and option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aquestive Therapeutics reported that Chief Legal Officer Thomas A. Zalewski received equity-based compensation. He was granted 100,000 shares of restricted Common Stock, which will vest in three annual installments of 25%, 25%, and 50%. He also received a Non-Qualified Stock Option for 75,000 shares of Common Stock at an exercise price of $4.135 per share, vesting on the same 25%/25%/50% schedule and expiring in 2036. After these awards, his reported holdings from this grant are 100,000 shares of Common Stock and options for 75,000 underlying shares.

Positive

  • None.

Negative

  • None.
Insider Zalewski Thomas A.
Role Chief Legal Officer
Type Security Shares Price Value
Grant/Award Non-Qualified Stock Option (right to buy) 75,000 $0.00 --
Grant/Award Common Stock 100,000 $0.00 --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 75,000 shares (Direct, null); Common Stock — 100,000 shares (Direct, null)
Footnotes (1)
  1. The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
Restricted Stock Grant 100,000 shares Common Stock award to Chief Legal Officer
Stock Option Grant 75,000 options Non-Qualified Stock Option for Common Stock
Option Exercise Price $4.135 per share Strike price for 75,000-share option grant
Common Shares After Grant 100,000 shares Total Common Stock reported following transaction
Options After Grant 75,000 options Total options reported following transaction
Option Expiration 2036-05-08 Expiration date of Non-Qualified Stock Option
restricted stock financial
"The Common Stock is represented by restricted stock which will vest in three annual installments"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy) with an exercise price of 4.1350"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
vest financial
"will vest in three annual installments with 25% on the 1st, 25% on the 2nd, and 50% on the 3rd installment"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion or exercise price of 4.1350 for the Non-Qualified Stock Option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration date of 2036-05-08 for the Non-Qualified Stock Option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zalewski Thomas A.

(Last)(First)(Middle)
C/O AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE

(Street)
WARREN NEW JERSEY 07059

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026A100,000(1)A$0100,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$4.13505/18/2026A75,000 (2)05/08/2036Common Stock75,000$075,000D
Explanation of Responses:
1. The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
2. The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
Remarks:
/s/ Hillary T. Yegen, as Attorney-in-Fact for Thomas Zalewski05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What are the key terms of Thomas Zalewski’s new AQST stock options?

The Non-Qualified Stock Option covers 75,000 shares of Common Stock at a $4.135 exercise price. The options vest 25%, 25%, and 50% over three annual installments and expire in 2036, offering long-dated upside if the share price exceeds the strike.

Is the Form 4 for AQST’s Thomas Zalewski a stock purchase or a grant?

The Form 4 reflects a grant or award acquisition, not an open-market purchase. Zalewski received restricted stock and stock options as part of compensation, with no reported cash paid per share in these transactions.

How many AQST shares does Thomas Zalewski hold after the reported transactions?

Following the reported awards, the filing shows Thomas Zalewski holding 100,000 shares of Common Stock from this grant and a Non-Qualified Stock Option covering 75,000 underlying shares, all held directly according to the Form 4 data.